4.5 Article

Flanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequences

期刊

CYTOTHERAPY
卷 10, 期 5, 页码 526-539

出版社

INFORMA HEALTHCARE
DOI: 10.1080/14653240802192636

关键词

gene therapy; integration-site analysis; LAM-PCR; polymerase chain reaction; retrovirus

资金

  1. British Society for Haematology Society Fellowship
  2. Doris Duke Distinguished Clinical Scientist Award
  3. Leukemia and Lymphoma Society [NCI PO1 CA94237]
  4. GCRC [RR00188]
  5. NATIONAL CANCER INSTITUTE [P50CA126752, P01CA094237] Funding Source: NIH RePORTER
  6. NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000188, K01RR000188] Funding Source: NIH RePORTER
  7. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U54HL081007] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Background Retroviral vectors are regularly used to transduce stem cells and their derivatives for experimental and therapeutic purposes. Because these vectors integrate semi-randomly into the cellular genome, analysis of integranated retroviral DNA/host cell DNA junctions (IHJ) facilitates clonality studies of engrafted cells, allowing their differentiation, survival and fate to be tracked. In the case of any adverse events, IHJ analysis can allow the identification of potentially oncogenic integration sites. At present, most measures to assess IHJ are complex, insensitive and may be subject to IHJ selection bias inherent to the technology used. Methods We have developed and validated a simple but effective technique for generating libraries of IHJ, which we term flanking-sequence exponential anchored-polymerase chain reaction (FLEA-PCR). Flanking-sequence random anchoring is used as an alternative to restriction enzyme digestion and cassette ligation to allow consistent detection of IHJ and decrease bias. Results Individual clones from plasmid libraries can be sequenced and assembled using custom-written software, and FLEA-PCR smears can be analyzed by capillary electrophoresis after digestion with restriction enzymes. Discussion This approach can readily analyze complex mixtures of IHJ, allowing localization of these sequences to their genomic sites. This approach should simplify analysis of retroviral integration.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Medicine, Research & Experimental

Combining phage display with SMRTbell next-generation sequencing for the rapid discovery of functional scFv fragments

Francesco Nannini, Lenart Senicar, Farhaan Parekh, Khai J. Kong, Alexander Kinna, Reyisa Bughda, James Sillibourne, Xihao Hu, Biao Ma, Yuchen Bai, Mathieu Ferrari, Martin A. Pule, Shimobi C. Onuoha

Summary: Phage display technology combined with next-generation sequencing is a cutting-edge method for monoclonal antibody isolation. Utilizing third-generation sequencing, this study successfully identified functional scFv antibodies from diverse libraries against CD160 and CD123 that were previously undetected by conventional screening methods.
Article Multidisciplinary Sciences

Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma

Giulia Agliardi, Anna Rita Liuzzi, Alastair Hotblack, Donatella De Feo, Nicolas Nunez, Cassandra L. Stowe, Ekaterina Friebel, Francesco Nannini, Lukas Rindlisbacher, Thomas A. Roberts, Rajiv Ramasawmy, Iwan P. Williams, Bernard M. Siow, Mark F. Lythgoe, Tammy L. Kalber, Sergio A. Quezada, Martin A. Pule, Sonia Tugues, Karin Straathof, Burkhard Becher

Summary: Research shows that local delivery of IL-12 combined with CAR-T cell therapy can achieve durable anti-tumor responses by enhancing cytotoxicity of CAR-T cells, reshaping the tumor microenvironment, promoting immune cell infiltration, and activating the myeloid compartment.

NATURE COMMUNICATIONS (2021)

Letter Oncology

Chimeric antigen receptor T cells for gamma-delta T cell malignancies

P. A. Wawrzyniecka, L. Ibrahim, G. Gritti, M. A. Pule, P. M. Maciocia

LEUKEMIA (2022)

Article Immunology

Depletion of T cells via Inducible Caspase 9 Increases Safety of Adoptive T-Cell Therapy Against Chronic Hepatitis B

Alexandre Klopp, Sophia Schreiber, Anna D. Kosinska, Martin Pule, Ulrike Protzer, Karin Wisskirchen

Summary: In this study, T cells were engineered to express HBV-specific receptors and inducible caspase 9 (iC9) as a safety switch, allowing for efficient recognition and killing of HBV-infected cells while also effectively depleting transferred T cells with unwanted hepatotoxicity both in vitro and in vivo.

FRONTIERS IN IMMUNOLOGY (2021)

Article Biochemical Research Methods

A compact and simple method of achieving differential transgene expression by exploiting translational readthrough

James E. Sillibourne, Giulia Agliardi, Matteo Righi, Katerina Smetanova, Grant Rowley, Simon Speller, Abigail Dolor, Katarina Lamb, Christopher Allen, Rajeev Karattil, Farhaan Parekh, Frederick Arce Vargas, Simon Thomas, Shaun Cordoba, Martin Pule

Summary: This study describes a simple method of achieving differential transgene expression by inserting stop codons and translational readthrough motifs (TRMs). TRMs can reduce downstream transgene expression and facilitate the controlled secretion of cytokines at therapeutically beneficial levels to prevent tumor growth. Due to their compact size and ease of introduction, TRMs are expected to be widely adopted in recombinant DNA engineering.

BIOTECHNIQUES (2022)

Article Hematology

Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia

Paul M. Maciocia, Patrycja A. Wawrzyniecka, Nicola C. Maciocia, Amy Burley, Thaneswari Karpanasamy, Sam Devereaux, Malika Hoekx, David O'Connor, Theresa Leon, Tanya Rapoz-D'Silva, Rachael Pocock, Sunniyat Rahman, Giuseppe Gritti, Diana C. Yanez, Susan Ross, Tessa Crompton, Owen Williams, Lydia Lee, Martin A. Pule, Marc R. Mansour

Summary: CCR9 expression is found in the majority of T-ALL cases, making it a potential target for CAR-T cell therapy. CAR-T cells targeting CCR9 can effectively inhibit leukemia cell proliferation without harming healthy T cells, providing a promising treatment strategy for T-ALL.
Article Hematology

Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells

Ilaria M. Michelozzi, Eduardo Gomez-Castaneda, Ruben V. C. Pohle, Ferran Cardoso Rodriguez, Jahangir Sufi, Pau Puigdevall Costa, Meera Subramaniyam, Efstratios Kirtsios, Ayad Eddaoudi, Si Wei Wu, Aleks Guvenel, Jonathan Fisher, Sara Ghorashian, Martin A. Pule, Christopher J. Tape, Sergi Castellano, Persis J. Amrolia, Alice Giustacchini

Summary: We have described a low-affinity second-generation CD19 chimeric antigen receptor (CAR) CAT that exhibits enhanced activation and cytokine polyfunctionality compared with high-affinity FMC63 CAR. This enhanced functionality is a result of antigen-dependent priming induced by residual CD19-expressing B cells. CAT CAR shows excellent toxicity profile, enhanced in vivo expansion, and long-term persistence in a phase 1 clinical study.

BLOOD ADVANCES (2023)

Article Biotechnology & Applied Microbiology

Dual targeting of CD19 and CD22 against B-ALL a novel-sensitivity aCD22 CAR

Evangelia Kokalaki, Biao Ma, Mathieu Ferrari, Thomas Grothier, Warren Hazelton, Somayya Manzoor, Eren Costu, Julia Taylor, Anna Bulek, Saket Srivastava, Isaac Gannon, Ram Jha, Rosalind Gealy, Lukas Stanczuk, Tatiana Rizou, Mathew Robson, Mohamed El-Kholy, Vania Baldan, Matteo Righi, James Sillibourne, Simon Thomas, Shimobi Onuoha, Shaun Cordoba, Martin Pule

Summary: CART cells recognizing CD19 effectively treat relapsed and refractory B-ALL and DLBCL, but CD19 loss often leads to relapse. Targeting a second antigen, CD22, can reduce antigen escape, but it is challenging due to low CD22 density and large structure. The characteristics and optimal strategy for CD22 CAR are not well-studied. Co-administration of CD19 and CD22 CARs is costly, and constructing single CARs targeting both antigens is difficult. A dual CART product, CAT/9A8 CART, is being tested in a phase I clinical study as a potential solution.

MOLECULAR THERAPY (2023)

Article Medicine, Research & Experimental

Novel Fas-TNFR chimeras that prevent Fas ligand-mediated kill and signal synergistically to enhance CAR T cell efficacy

Callum McKenzie, Mohamed El-Kholy, Farhaan Parekh, Mathew Robson, Katarina Lamb, Christopher Allen, James Sillibourne, Shaun Cordoba, Simon Thomas, Martin Pule

Summary: The hostile tumor microenvironment hampers the effectiveness of adoptive cell therapies. Disrupting the Fas death receptor, which initiates apoptosis, could enhance CAR T cell efficacy. By screening a library of Fas-TNFR proteins, researchers identified a novel chimera called Fas-CD40 that not only prevented Fas ligands from killing cells, but also synergistically enhanced CAR T cell efficacy.

MOLECULAR THERAPY-NUCLEIC ACIDS (2023)

Article Medicine, Research & Experimental

Efficient clinical-grade ?-retroviral vector purification by high-speed centrifugation for CAR T cell manufacturing

Leila Mekkaoui, Jose G. Tejerizo, Sara Abreu, Lydie Rubat, Aleksandra Nikoniuk, William Macmorland, Claire Horlock, Sofia Matsumoto, Sarah Williams, Koval Smith, Juliet Price, Saket Srivastava, Rehan Hussain, Mohammad Amin Banani, William Day, Elena Stevenson, Meghan Madigan, Jie Chen, Ravin Khinder, Shahed Miah, Simon Walker, Michael Ade-Onojobi, Sabine Domining, James Sillibourne, Marianna Sabatino, Vladimir Slepushkin, Farzin Farzaneh, Martin Pule

Summary: A simple one-step purification method using high-speed centrifugation was developed to purify transiently produced ?-RV for clinical application. The method achieved concentration of viral titers in the range of 10(7)-10(8) TU/mL with >80% overall recovery. Purification of ?-RV using this method resulted in significantly lower impurities compared to stable producer cell line vectors approved for clinical application.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2023)

Article Biochemistry & Molecular Biology

Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia

Nathaniel D. Anderson, Jack Birch, Theo Accogli, Ignacio Criado, Eleonora Khabirova, Conor Parks, Yvette Wood, Matthew D. Young, Tarryn Porter, Rachel Richardson, Sarah J. Albon, Bilyana Popova, Andre Lopes, Robert Wynn, Rachael Hough, Satyen H. Gohil, Martin Pule, Persis J. Amrolia, Sam Behjati, Sara Ghorashian

Summary: In this study, the persistence of CD19 CAR-T cells in children with R/R B-ALL was analyzed, revealing a specific gene signature associated with long-lived CAR-T cells. This signature was found to be present in both children and adults with persistent CD19 CAR-T cells, indicating its potential as a universal transcriptional signature.

NATURE MEDICINE (2023)

Article Oncology

Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies

Ernesto Lopez, Rajesh Karattil, Francesco Nannini, Gordon Weng-Kit Cheung, Lilian Denzler, Felipe Galvez-Cancino, Sergio Quezada, Martin A. Pule

Summary: The combination of CAR T-cell therapy and MCT-1 blockade demonstrates improved cytotoxicity and antitumoral control in B-cell lymphoma, indicating the potential of targeting lactate metabolism in CAR T-cell therapies.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Article Oncology

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy

Lydia Lee, Wen Chean Lim, Daria Galas-Filipowicz, Kent Fung, Julia Taylor, Dominic Patel, Zulaikha Akbar, Elena Alvarez Mediavilla, Patrycja Wawrzyniecka, Debarati Shome, Rogier M. Reijmers, Trillian Gregg, Leigh Wood, William Day, Virginie Cerec, Mathieu Ferrari, Simon Thomas, Shaun Cordoba, Shimobi Onuoha, Nushmia Khokhar, Vijay Peddareddigari, Muhammad Al-Hajj, Jim Cavet, Sonja Zweegman, Manuel Rodriguez-Justo, Kwee Yong, Martin Pule, Rakesh Popat

Summary: In this study, a ligand-based CAR targeting two myeloma antigens was constructed and evaluated in a clinical trial. The results showed that the APRIL CAR was well tolerated, but the clinical responses were disappointing. Comparing with other BCMA CARs, the APRIL CAR exhibited functional deficiencies due to reduced target binding by cell-expressed ligand.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Article Hematology

Activation priming and cytokine polyfunctionality modulate the enhanced functionality of low-affinity CD19 CAR T cells

Ilaria M. Michelozzi, Eduardo Gomez-Castaneda, Ruben V. C. Pohle, Ferran Cardoso Rodriguez, Jahangir Sufi, Pau Puigdevall Costa, Meera Subramaniyam, Efstratios Kirtsios, Ayad Eddaoudi, Si Wei Wu, Aleks Guvenel, Jonathan Fisher, Sara Ghorashian, Martin A. Pule, Christopher J. Tape, Sergi Castellano, Persis J. Amroia, Alice Giustacchini

Summary: A low-affinity second-generation CD19 CAR showed improved expansion, cytotoxicity, and antitumor efficacy compared to a high-affinity CAR in preclinical models. In a phase 1 clinical study, the low-affinity CAR demonstrated an excellent toxicity profile and long-term persistence. In vitro characterization revealed that low-affinity CAR T cells had enhanced activation and a distinct transcriptomic and protein profile, with increased activation and cytokine polyfunctionality compared to high-affinity CAR T cells.

BLOOD ADVANCES (2023)

Article Hematology

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

Claire Roddie, Lazaros J. Lekakis, Maria A. V. Marzolini, Aravind Ramakrishnan, Yiyun Zhang, Yanqing Hu, Vijay G. R. Peddareddigari, Nushmia Khokhar, Robert Chen, Silvia Basilico, Meera Raymond, Frederick Arce Vargas, Kevin Duffy, Wolfram Brugger, Maeve A. O'Reilly, Leigh Wood, David C. Linch, Karl S. Peggs, Carlos Bachier, Elizabeth Lihua Budde, Connie Lee Batlevi, Nancy Bartlett, David Irvine, Eleni Tholouli, Wendy Osborne, Kirit M. Ardeshna, Martin A. Pule

Summary: This study evaluated the efficacy of CD19/22 dual-targeting CAR-T (AUTO3) plus pembrolizumab in relapsed/refractory large B-cell lymphoma. The results showed that the AUTO3 plus pembrolizumab treatment regimen was safe for patients and provided durable remissions in complete responders.
暂无数据